SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Mrinal M. Patnaik, Sameer A. Parikh, Curtis A. Hanson, Ayalew Tefferi, Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review, British Journal of Haematology, 2014, 165, 3
  2. 2
    Sally B. Killick, Chris Carter, Dominic Culligan, Christopher Dalley, Emma Das-Gupta, Mark Drummond, Helen Enright, Gail L. Jones, Jonathan Kell, Juliet Mills, Ghulam Mufti, Jane Parker, Kavita Raj, Alexander Sternberg, Paresh Vyas, David Bowen, Guidelines for the diagnosis and management of adult myelodysplastic syndromes, British Journal of Haematology, 2014, 164, 4
  3. 3
    Ramon V. Tiu, Mikkael A. Sekeres, Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes, Current Opinion in Hematology, 2014, 21, 2, 131

    CrossRef

  4. 4
    Sameer A. Parikh, Ayalew Tefferi, Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management, American Journal of Hematology, 2013, 88, 11
  5. 5
    Gopi K Prithviraj, Blessy M Mathew, Rami K Komrokji, Alan F List, Eric Padron, Chronic myelomonocytic leukemia: a review of the molecular biology, prognostic models and treatment, International Journal of Hematologic Oncology, 2013, 2, 2, 151

    CrossRef

  6. 6
    Raphael Itzkson, Pierre Fenaux, Eric Solary, Chronic myelomonocytic leukemia: Myelodysplastic or myeloproliferative?, Best Practice & Research Clinical Haematology, 2013, 26, 4, 387

    CrossRef

  7. 7
    Luana Fianchi, Marianna Criscuolo, Massimo Breccia, Luca Maurillo, Flavia Salvi, Pellegrino Musto, Giovanna Mansueto, Gianluca Gaidano, Carlo Finelli, Antonietta Aloe-Spiriti, Valeria Santini, Mariangelo Greco, Stefan Hohaus, Giuseppe Leone, Maria Teresa Voso, High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study, Leukemia & Lymphoma, 2013, 54, 3, 658

    CrossRef

  8. 8
    Maro Ohanian, Stefan Faderl, Farhad Ravandi, Naveen Pemmaraju, Guillermo Garcia-Manero, Jorge Cortes, Zeev Estrov, Is acute myeloid leukemia a liquid tumor?, International Journal of Cancer, 2013, 133, 3
  9. 9
    Omid Tavana, Wei Gu, p53 and DNA methylation suppress the TRAIN to cell death, Cell Cycle, 2013, 12, 1, 9

    CrossRef

  10. 10
    Lionel Adès, Mikkael A. Sekeres, Alice Wolfromm, Melissa L. Teichman, Ramon V. Tiu, Raphael Itzykson, Jaroslaw P. Maciejewski, Francois Dreyfus, Alan F. List, Pierre Fenaux, Rami S. Komrokji, Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine, Leukemia Research, 2013, 37, 6, 609

    CrossRef

  11. You have full text access to this OnlineOpen article11
    Sameer A. Parikh, Ayalew Tefferi*, Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management, American Journal of Hematology, 2012, 87, 6
  12. 12
    H Cheng, V G Kirtani, U Gergis, Current status of allogeneic HST for chronic myelomonocytic leukemia, Bone Marrow Transplantation, 2012, 47, 4, 535

    CrossRef

  13. 13
    Giovanni Barosi, Emerging targeted therapies in myelofibrosis, Expert Review of Hematology, 2012, 5, 3, 313

    CrossRef

  14. 14
    E-J Geutjes, P K Bajpe, R Bernards, Targeting the epigenome for treatment of cancer, Oncogene, 2012, 31, 34, 3827

    CrossRef

  15. 15
    Lionel Adès, Raphael Itzykson, Pierre Fenaux, Treatment of Advanced Myelodysplastic Syndrome With Demethylating Agents: Azacitidine, Seminars in Hematology, 2012, 49, 4, 323

    CrossRef

  16. 16
    Peter Rohon, Jana Vondrakova, Anna Jonasova, Milena Holzerova, Marie Jarosova, Karel Indrak, Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports, Case Reports in Hematology, 2012, 2012, 1

    CrossRef

  17. 17
    Rubens Costa, Haifaa Abdulhaq, Bushra Haq, Richard K. Shadduck, Joan Latsko, Mazen Zenati, Folefac D. Atem, James M. Rossetti, Entezam A. Sahovic, John Lister, Activity of azacitidine in chronic myelomonocytic leukemia, Cancer, 2011, 117, 12
  18. 18
    T. Braun, R. Itzykson, A. Renneville, B. de Renzis, F. Dreyfus, K. Laribi, K. Bouabdallah, N. Vey, A. Toma, C. Recher, B. Royer, B. Joly, A. Vekhoff, I. Lafon, L. Sanhes, G. Meurice, C. Orear, C. Preudhomme, C. Gardin, L. Ades, M. Fontenay, P. Fenaux, N. Droin, E. Solary, Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial, Blood, 2011, 118, 14, 3824

    CrossRef

  19. 19
    S. D. Gore, New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome, Hematology, 2011, 2011, 1, 550

    CrossRef

  20. 20
    Inge Verbrugge, Ricky W Johnstone, Michael Bots, Promises and challenges of anticancer drugs that target the epigenome, Epigenomics, 2011, 3, 5, 547

    CrossRef

  21. 21
    Ulrike Bacher, Torsten Haferlach, Susanne Schnittger, Hans Kreipe, Nicolaus Kröger, Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia, British Journal of Haematology, 2011, 153, 2
  22. 22
    Fabio P. S. Santos, Hagop Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, The Search for Better Prognostic Models in Myelodysplastic Syndromes, Current Hematologic Malignancy Reports, 2011, 6, 1, 13

    CrossRef

  23. 23
    Marcelo Iastrebner, Jun Ho Jang, Elsa Nucifora, Kihyun Kim, Federico Sackmann, Dong Hwan Kim, Sergio Orlando, Chul Won Jung, Ana Basquiera, Graciela Klein, Fernando Santini, Haydee I. Bernard, Jorge Korin, Gustavo Taborda, Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience, Leukemia & Lymphoma, 2010, 51, 12, 2250

    CrossRef

  24. 24
    G. Garcia-Manero, Prognosis of Myelodysplastic Syndromes, Hematology, 2010, 2010, 1, 330

    CrossRef

  25. 25
    R A Mesa, S Verstovsek, C Rivera, A Pardanani, K Hussein, T Lasho, W Wu, A Tefferi, 5-Azacitidine has limited therapeutic activity in myelofibrosis, Leukemia, 2009, 23, 1, 180

    CrossRef

  26. 26
    Tejas V. Patel, Helmut G. Rennke, J. Mark Sloan, Daniel J. DeAngelo, David M. Charytan, A Forgotten Cause of Kidney Injury in Chronic Myelomonocytic Leukemia, American Journal of Kidney Diseases, 2009, 54, 1, 159

    CrossRef

  27. 27
    David P. Steensma, Decitabine treatment of patients with higher-risk myelodysplastic syndromes, Leukemia Research, 2009, 33, S12

    CrossRef

  28. 28
    A. Hoglund, L. M. Nilsson, L. P. Forshell, K. H. Maclean, J. A. Nilsson, Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine, Blood, 2009, 113, 18, 4281

    CrossRef

  29. 29
    Connie C. Cortez, Peter A. Jones, Chromatin, cancer and drug therapies, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 647, 1-2, 44

    CrossRef

  30. 30
    P.W. Wijermans, B. Rüter, M.R. Baer, J.L. Slack, H.I. Saba, M. Lübbert, Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML), Leukemia Research, 2008, 32, 4, 587

    CrossRef

  31. 31
    Michael R Hinckley, Sarah N Walsh, István Molnár, Daniel J Sheehan, Omar P Sangueza, Gil Yosipovitch, Generalized Granuloma Annulare As an Initial Manifestation of Chronic Myelomonocytic Leukemia: A Report of 2 Cases, The American Journal of Dermatopathology, 2008, 30, 3, 274

    CrossRef

  32. 32
    Sreekanth Donepudi, Ryan J. Mattison, Jane E. Kihslinger, Lucy A. Godley, Modulators of DNA methylation and histone acetylation, Update on Cancer Therapeutics, 2007, 2, 4, 157

    CrossRef

  33. 33
    David P. Steensma, Bret B. Friday, Monocytic skin nodules in chronic myelomonocytic leukemia: Clinical response to decitabine therapy, Leukemia & Lymphoma, 2007, 48, 8, 1628

    CrossRef

  34. 34
    Jane E. Kihslinger, Lucy A. Godley, The use of hypomethylating agents in the treatment of hematologic malignancies, Leukemia & Lymphoma, 2007, 48, 9, 1676

    CrossRef